3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Gynecologic
2
Genitourinary
2
Gastrointestinal
2
Thoracic
1
Sarcoma
1
Head & Neck
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Stomach Neoplasms
12
Colorectal Neoplasms
10
Adenocarcinoma
6
Breast Neoplasms
5
Pancreatic Neoplasms
4
Neoplasm Metastasis
4
Esophageal Neoplasms
4
Sarcoma
2
Salivary Gland Neoplasms
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms
2
Melanoma
2
HER2-positive Gastric Cancer
2
Gastrointestinal Neoplasms
2
Endometrial Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Renal Cell
2
Adenocarcinoma Of Esophagus
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Rectal Neoplasms
1
Neoplasm, Residual
1
Mouth Neoplasms
1
Interventions
pembrolizumab
17
Surveys and Questionnaires
12
Specimen Handling
11
Docetaxel
11
Nivolumab
9
Interviews as Topic
9
Standard of Care
8
Gemcitabine
8
Early Intervention, Educational
8
olaparib
7
enzalutamide
7
Magnetic Resonance Spectroscopy
7
Psychiatric Rehabilitation
6
Paclitaxel
6
durvalumab
5
Trastuzumab
5
Radiotherapy
5
Ipilimumab
5
Carboplatin
5
Bevacizumab
5
pertuzumab
4
palbociclib
4
cabozantinib
4
atezolizumab
4
abiraterone
4
Therapeutics
4
Taxes
4
Oxaliplatin
4
Methods
4
Immunoglobulin G
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
trastuzumab deruxtecan
×
Gastrointestinal
×
Clear all
NCT05417594
2026-06-02
CERTIS1
AstraZeneca
Phase 1/2
Recruiting
695 enrolled
NCT07124000
2026-06-01
DP-04
AstraZeneca
Recruiting
100 enrolled